LifePoint Completes Impact(TM) Test System Beta

- Data Needed for the FDA 510(k) Submission

and Product Release Ready to Be Compiled -



Apr 02, 2001, 01:00 ET from LifePoint, Inc.

    ONTARIO, Calif., April 2 /PRNewswire/ -- LifePoint, Inc. (Amex:   LFP) today
 announced the completion of the beta version of the Impact(TM) Test System.
 This beta version is a fully operational instrument, which, along with the
 injection molded reagent cassette, will be used for the initiation of field
 evaluations in the next few weeks and for marketing pilots shortly thereafter.
     "The successful completion of the beta test system is a long-awaited final
 step," stated Thomas F. Foley, Senior Vice President Research and Development.
 "Now our clinical studies can begin and we will generate the data to be used
 for the Impact Test System product claims.  We are now manufacturing
 additional beta units to be used for the data collection at our clinical
 evaluation sites that will begin this month.  Subsequent to the clinical
 evaluations, the law enforcement community and industrial workplace personnel
 will also evaluate our beta system at the marketing pilot sites.  Based on the
 beta system performance, we expect our field evaluations to go quickly and to
 confirm our performance expectations for the Impact Test System."
     "Everyone at LifePoint is extremely excited to finally see the completion
 of the integrated beta version of the Impact Test System," stated Linda H.
 Masterson, President and Chief Executive Officer.  "We look forward to finally
 placing the system in the hands of our future customers and showing them how
 the system will efficiently and cost-effectively meet their needs.  Our
 clinical evaluation sites are ready to initiate the studies needed to generate
 the data for the FDA 510(k) submission, as well as the data needed for
 marketing.  These results will show customers how our one step non-invasive
 product compares to the commonly used breath alcohol testing and urine drug
 testing methods.  Most importantly our product launch for the law enforcement
 and industrial markets remains on schedule for the second quarter of 2001."
 
     About LifePoint, Inc.
     LifePoint, Inc. is a medical technology company designing the Impact Test
 System -- a rapid diagnostic testing, screening, and therapeutic drug
 monitoring device for use in the workplace, home health care, ambulances,
 pharmacies and law enforcement.  LifePoint is focused on the commercialization
 of the flow immunosensor technology licensed from the Naval Research
 Laboratories.  This patented technology, when used in conjunction with
 LifePoint's own patented and proprietary technologies on using saliva as a
 non-invasive test specimen, will allow for the development of a broadly
 applicable non-invasive, rapid, on-site diagnostic test system.  The first
 product being commercialized is for the simultaneous detection of drugs of
 abuse and alcohol, estimated to be over a $1.6 billion market by 2002.
 
     This press release contains forward-looking statements regarding future
 events and the future performance of LifePoint, Inc. that involve risks and
 uncertainties that could cause actual results to differ materially.  These
 risks include, but are not limited to, the completion of product
 commercialization, the need for additional funding, the initiation and
 completion of clinical trials, dependence on third parties for clinical
 testing and marketing, and market acceptance.  These risks are described in
 further detail in the Company's reports filed with the Securities and Exchange
 Commission.
 
     LifePoint(TM) and Impact(TM) are trademarks of LifePoint, Inc.
 
 
     Contact:
 
     LifePoint, Inc.                         Noonan/Russo Communications, Inc.
     Linda H. Masterson, CEO & President     Brian Maude x 360
     (909) 418-3000 x 400                    (415) 677-4455
     e-mail:  lifepoint@LFPT.com             e-mail: b.maude@noonanrusso.com
     Web site - www.lifepointinc.com         Web site - www.noonanrusso.com
 
 

SOURCE LifePoint, Inc.
    ONTARIO, Calif., April 2 /PRNewswire/ -- LifePoint, Inc. (Amex:   LFP) today
 announced the completion of the beta version of the Impact(TM) Test System.
 This beta version is a fully operational instrument, which, along with the
 injection molded reagent cassette, will be used for the initiation of field
 evaluations in the next few weeks and for marketing pilots shortly thereafter.
     "The successful completion of the beta test system is a long-awaited final
 step," stated Thomas F. Foley, Senior Vice President Research and Development.
 "Now our clinical studies can begin and we will generate the data to be used
 for the Impact Test System product claims.  We are now manufacturing
 additional beta units to be used for the data collection at our clinical
 evaluation sites that will begin this month.  Subsequent to the clinical
 evaluations, the law enforcement community and industrial workplace personnel
 will also evaluate our beta system at the marketing pilot sites.  Based on the
 beta system performance, we expect our field evaluations to go quickly and to
 confirm our performance expectations for the Impact Test System."
     "Everyone at LifePoint is extremely excited to finally see the completion
 of the integrated beta version of the Impact Test System," stated Linda H.
 Masterson, President and Chief Executive Officer.  "We look forward to finally
 placing the system in the hands of our future customers and showing them how
 the system will efficiently and cost-effectively meet their needs.  Our
 clinical evaluation sites are ready to initiate the studies needed to generate
 the data for the FDA 510(k) submission, as well as the data needed for
 marketing.  These results will show customers how our one step non-invasive
 product compares to the commonly used breath alcohol testing and urine drug
 testing methods.  Most importantly our product launch for the law enforcement
 and industrial markets remains on schedule for the second quarter of 2001."
 
     About LifePoint, Inc.
     LifePoint, Inc. is a medical technology company designing the Impact Test
 System -- a rapid diagnostic testing, screening, and therapeutic drug
 monitoring device for use in the workplace, home health care, ambulances,
 pharmacies and law enforcement.  LifePoint is focused on the commercialization
 of the flow immunosensor technology licensed from the Naval Research
 Laboratories.  This patented technology, when used in conjunction with
 LifePoint's own patented and proprietary technologies on using saliva as a
 non-invasive test specimen, will allow for the development of a broadly
 applicable non-invasive, rapid, on-site diagnostic test system.  The first
 product being commercialized is for the simultaneous detection of drugs of
 abuse and alcohol, estimated to be over a $1.6 billion market by 2002.
 
     This press release contains forward-looking statements regarding future
 events and the future performance of LifePoint, Inc. that involve risks and
 uncertainties that could cause actual results to differ materially.  These
 risks include, but are not limited to, the completion of product
 commercialization, the need for additional funding, the initiation and
 completion of clinical trials, dependence on third parties for clinical
 testing and marketing, and market acceptance.  These risks are described in
 further detail in the Company's reports filed with the Securities and Exchange
 Commission.
 
     LifePoint(TM) and Impact(TM) are trademarks of LifePoint, Inc.
 
 
     Contact:
 
     LifePoint, Inc.                         Noonan/Russo Communications, Inc.
     Linda H. Masterson, CEO & President     Brian Maude x 360
     (909) 418-3000 x 400                    (415) 677-4455
     e-mail:  lifepoint@LFPT.com             e-mail: b.maude@noonanrusso.com
     Web site - www.lifepointinc.com         Web site - www.noonanrusso.com
 
 SOURCE  LifePoint, Inc.